Premium
ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY
Author(s) -
Witzig T.E.,
Maddocks K.,
Vos S.,
Lyons R.,
Edenfield W.,
Sharman J.,
Vose J.,
Yimer H.,
Wei H.,
Chan E.,
Patel P.,
Di Simone C.,
Gandhi M.,
Vaughn J.,
Kolibaba K.,
Cheson B.,
Samaniego F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.139_2630
Subject(s) - medicine , gastroenterology , pembrolizumab , neutropenia , adverse effect , diffuse large b cell lymphoma , pneumonitis , chemoimmunotherapy , rituximab , progressive disease , oncology , surgery , lymphoma , cancer , chemotherapy , lung , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom